T-2 mycotoxin

Amlan International Set To Exhibit Natural Mineral Technology At International Production And Processing Expo (IPPE)

Retrieved on: 
Thursday, January 11, 2024
Livestock, Health, Poultry, Salmonella, Innovation, Government, T-2 mycotoxin, Poultry World, ODC, IPSF, T-2, Research, Marketing strategy, IPPE, Coccidiosis, Animal feed

Amlan is set to showcase its commitment to advancing animal health and feed technology through multiple on-site presentations.

Key Points: 
  • Amlan is set to showcase its commitment to advancing animal health and feed technology through multiple on-site presentations.
  • The Amlan team looks forward to engaging with an international audience of animal production professionals, sharing comprehensive insights into its range of mineral based feed additives with attendees, media, and fellow exhibitors at booth B15005.
  • The seminar will focus on Natural Solutions for Gut Health and is being hosted by Poultry World.
  • “Our team is looking forward to sharing the latest NeutraPath research,” said Dr. Wade Robey, President, Amlan International.

Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense

Retrieved on: 
Thursday, January 5, 2023
Government, U.S. Department of Defense Strategy for Operating in Cyberspace, Public health, CCC, RSDL, Emergent BioSolutions, Skin, United States Department of Defense, Canadian Commercial Corporation, MCM, T-2, NYSE, T-2 mycotoxin, EBS, Emergent, Pharmaceutical industry

GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military.

Key Points: 
  • GAITHERSBURG, Md., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity procurement contract with a maximum value up to $379.6 million to supply RSDL® (Reactive Skin Decontamination Lotion Kit) for use by all branches of the U.S. military.
  • Emergent’s Canadian Subsidiary will serve as the sole subcontractor to deploy RSDL® to the U.S. Department of Defense (DoD) through a new contract award to the Canadian Commercial Corporation (CCC).
  • The new contract has a base year, which began in December 2022, and four single year option renewals.
  • RSDL has been procured for military and first responder use for over a decade and has been deployed in over 30 countries.

CytoSorb Treatment Improves Rat Survival Following Lethal Intravenous Dose of Fungal Aflatoxin

Retrieved on: 
Wednesday, January 22, 2020
Chemical compounds, Aflatoxins, Organic compounds, Chemical substances, Hepatology, Food safety, Aflatoxin B1, Polyketides, Teratogens, Mycotoxin, Hepatocellular carcinoma, T-2 mycotoxin

Aflatoxin is one of the most potent liver carcinogens known and can lead to hepatic cancer with chronic exposure.

Key Points: 
  • Aflatoxin is one of the most potent liver carcinogens known and can lead to hepatic cancer with chronic exposure.
  • We have previously reported that CytoSorb rapidly and effectively adsorbs more than 90% of aflatoxin and the T2 mycotoxin from whole blood in an in vitro recirculation system scaled for human treatment in 1 hour.
  • In the current study, Dr. Karl-Gustav Ruggeberg, PhD and colleagues further investigated if CytoSorb blood purification could rescue rats administered with a lethal (LD90) intravenous dose of aflatoxin B1.
  • The broad-spectrum ability of CytoSorb to rapidly reduce aflatoxin and a wide variety of other inflammatory toxins is key to its efficacy in many diseases.